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2. List of tables and figures 
 
Table 1.Patient and tumour characteristics 
 
 N (%) 
Gender  
             Female 
             Male 
 
4 (30.8%) 
9 (69.2%) 
Age (y) at initial visit 
             Mean 
 
 
60.4y 
Range 45-79y 
Tumour location 
             Left 
             Right 
 
7 (53.8%) 
6 (46.2%) 
Koos classification 
Stage I (intracanalicular) 
Stage II (CPA) 
Stage III (CPA reaching pons) 
Stage IV (deforming pons shifting 4th ventricle)  
 
1   (7.7%) 
9   (69.2%) 
3   (23.1%) 
0 
Alive 
          Yes 
          No 
           
 
8 (61.5%) 
5 (38.5%) 
 
Previous surgery 
          Yes 
           No 
 
2 (15.4%) 
11 (84.6%) 
Tumour size (MLD)  
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        <10mm 
        11-20mm 
        21-30mm 
        31-40mm 
        >41mm 
 
0 
12 (92.3%) 
1 (7.7%) 
0 
0 
ECOG  
            0 
            1 
            2 
            3/4 
           
 
0 
12 (92.3%) 
1 (7.7%) 
0 
 
Neurofibromatosis type II 2 (15.4%) 
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Figure 1.Individual tumour response trend after SRT  
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Figure 2. Changes in tumour volume from Baseline  
A. Wilcoxon plot depicting pre- and post-RT volumes for 10 patients , at time of 
last imaging (range 18- 50 months) . Maximum, minumum and median TV are 
depicted by the superior, inferior and middle lines. 
B. Waterfall plot showing post treatment volumes.  Stable disease is between 
the dashed lines ( -20% and +20% change in tumour volume).Tumour 
progression can be seen in 3 patients, stable disease in 3 patients, and 
regression in 4 patients.  
 
 
Figure 3. Kaplan-Meier curve showing radiological tumour control after hypofractionated 
SRT 
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Correlation of radiologist reported 2D TV versus calculated TV  
Radiologist reported axial measurements were plotted against calculated TV for MRIs (fig 4). 
 
Figure 4. Radiology correlation 
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3. Abbreviations	
 
 
AN  Acoustic neuromas  
RT  Radiotherapy   
SRS Stereotactic radiosurgery 
SRT  Stereotactic radiotherapy 
DCA Dynamic conformal arc 
CPA Cerebellopontine angle 
GSH Groote Schuur Hospital 
MRI Magnetic resonance imaging 
Gd Gadolinium  
NF2 Neurofibromatosis type 2 
TPS Treatment planning system 
TP True positive 
TN True negative 
FP False positive 
FN False negative 
  
 
CT Computed tomography 
Linac Linear accelerator 
MLD Maximum linear diameter 
LMIC Low and middle income country 
IGRT Image guided radiotherapy 
RTOG Radiation Therapy Oncology 
Group 
ECOG Eastern Cooperative Oncology 
Group 
CN Cranial nerve 
GTV gross tumour volume 
PTV  Planning tumour volume 
TV Tumour volume 
BTV Baseline tumour volume 
RTV Radiologist tumour volume 
  
	 11	
4. Abstract 
	
Background:  
Stereotactic radiosurgery (SRS) is the gold standard for treatment of small and medium 
sized tumours, although fractionated regimens are well described. Access is limited in 
resource-constrained settings. There are no South African data describing outcomes of AN 
patients treated with fractionated stereotactic radiotherapy (SRT) using photons. We 
describe clinical and radiological outcomes of AN patients treated with SRT at an academic 
centre in Cape Town, South Africa. 
Objectives:  
To describe patient demographics, tumour characteristics and patients’ symptoms and 
changes in symptoms at follow-up. To investigate tumour local control (LC) rates at last 
follow up MRI, and compare LC rates described for SRS in the literature. To correlate 
radiologists’ serial 2D maximum linear diameter (MLD) measurements with calculated 3D 
tumour volume (TV).	 
Methods: 
Fifteen AN patients treated with modified SRT (18.0gy/3fractions, were identified from the 
planning database; 13 were included. Patient data and tumour characteristics (size, laterality 
and previous surgery) were retrospectively extracted from clinic folders. Initial planning data 
was accessed and checked. Tumour volumes were contoured by the author on all 
subsequent MRI’s per patient and validated by a second investigator; tumour volume (TV) 
was automatically calculated. Radiologist’s 2D MLDs were compared with 3D TV. Sensitivity 
and specificity of radiologist reported change of MLD as a measure of actual change in TV 
was calculated. LC was calculated, from time of treatment to time of last MRI or time of 
progression (defined as ≥20% increase in TV). 
Results:  
Mean age was 60.4years (range 45-79years), with 4 (30.8%) being female.  Seven patients 
(53.8%) had left sided tumours and median tumour size was 1.15cm3 (mean 1.59 cm3; range 
0.62-3.35 cm3). Nine patients (69.2%) had Koos stage 2 ANs, 3 (23.1%) had stage 3 
tumours and 1 (7.7%) had a stage I tumour. Two patients had NF2.Median follow-up time 
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was 29 months (range 0-50 months). Median baseline TV, as was 1.15 cm3 (mean 1.59cm3 
with range 0.62-3.35 cm3).  
Three patients had no follow-up MRIs: 2 demised and 1 declined further follow-up. In total 5 
patients died, 4 of unrelated causes and 1 of unknown cause (median time to death after RT 
24 months, range 6 – 36 months). LC was 74% at 36months. Hearing preservation rate was 
67%. No new facial or trigeminal nerve symptoms were noted. Radiologists correctly 
reported tumour growth in 100% of tumours that grew, and specificity was 77.3% in those 
that were stable. 
Conclusion:  
This is the first local study in hypofractionated SRT using photons. We show lower LC rates 
than seen in literature; our numbers are small and short follow up time short, with high 
attrition rates. Acute treatment toxicities were absent. Longer term follow-up is needed to 
assess late RT effects. A prospective study using this method of treatment would better 
define LC. 
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5. Introduction and Literature Review 
 
Anatomy and pathology 
 Acoustic neuromas (AN) are benign intracranial lesions (WHO I) arising from the myelin 
producing Schwann cells which encapsulate the vestibulocochlear nerve(CNVIII). Ninety 
percent of tumours have their origin in the inferior division of CN VIII(1). Tumours usually 
arise from the nerve in the internal auditory canal (IAC), where the narrow bony anatomy 
limits expansion, but may occur anywhere along its length. Extrameatal tumours expand into 
the cerebellopontine angle (CPA) and may compress the brainstem. Part of the nerve’s 
course in the posterior fossa and base of skull runs close to the facial and trigeminal nerves 
(CN VII and CN V respectively), and tumours found here may cause CN neuropathies. 
Epidemiology 
 Relatively common tumours, ANs make up 5-10% of adult intracranial tumours and as much 
as 80-85% of cerebellopontine angle (CPA) tumours (2-4) They arise mainly unilaterally 
(90%) where they are sporadic. Where bilateral, they are usually associated with 
neurofibromatosis type 2 (NF2). The median age at diagnosis is 55 years, with a roughly 
equal female and male distribution (3). The incidence of ANs varies greatly across time 
periods and geographical areas, from 1.9-20 ANs/million of the population/year. A Polish 
group described a crude surgical incidence of 1.9 AN/million inhabitants per year (based on 
a questionnaire answered by ENT and neurosurgeons) (5). In contrast in 2004, a large 
Danish group quoted an incidence in their population of 17.4/million/year(6). These data are 
based on a registry of AN which is updated prospectively with all newly diagnosed tumours 
and are thus more accurate. Other registry based data have been published by groups in 
Cambridge, England (annual incidence of 20 ANs/million inhabitants for the 10-year period 
1981-1991)(7), and Manitoba, Canada (7/million/year for the period 1987-1991)(8). Part of 
the increasing incidence noted is explained by earlier diagnosis and availability of 
sophisticated imaging modalities such as magnetic resonance imaging (MRI) and computed 
tomography (CT)(3, 9). Median size has decreased with earlier diagnosis, while age at 
diagnosis has remained static. One theory to explain this phenomenon is that elderly 
patients are also being offered imaging earlier(3) 
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Natural history 
 Decisions for treatment of these benign tumours depend largely on their growth patterns, as 
it is when they undergo progressive growth, especially in the CPA, that they can cause 
significant morbidity and rarely mortality. Much has been published in the literature on the 
natural history of ANs, but numbers in these observational studies are small(10-13). They 
are also fraught with patient selection bias (e.g. older patients with co-morbidities, those 
unwilling to have an intervention or unfit for surgery).  
A small study by Hoistad et al found only 44% of tumours displayed growth during a mean 
follow-up period of 28.2 months. They grew on average 2.17mm per annum(14) 
More recently a systematic review was published reviewing studies on patterns of AN growth 
in patients undergoing observation(4). A total of 42 papers were analysed in this review. It 
confirmed that there are no predictors for growth including age, gender, tumour size at 
baseline, laterality or symptoms at presentation. The authors noted that most studies did not 
specifically describe patterns of growth, but the few that did detail these patterns, identified 
multiple patterns of variable frequencies: these included continuous growth in 15 to 25%, 
stability followed by growth (13-20%), growth to stability or regression (3-40%), stability (20-
50%) and regression in 5-8%(15, 16). 
In the largest study on the natural history of ANs, a Danish group published data on their 
one-centre cohort of all AN patients diagnosed in Denmark over 30 years until 2005 (17). Of 
these 1,818 patients, 729 were observed with serial MRIs and 552 had at least 2 scans. The 
authors defined growth in IAC tumours as extension out of the internal auditory meatus, 
while an increase in largest diameter of 2mm or more was considered growth in CPA 
tumours. Of the 230 IAC tumours, 17% expanded to become extrameatal. This was 
statistically significantly fewer than those extrameatal tumours that exhibited growth (28.9% 
of 322; p<0.001). Of those that grew, neither the IAC nor the CPA tumours exhibited any 
growth after 5 years of observation post diagnosis; as such they suggest annual scans for 
the initial 5 years, and thereafter scans are repeated biennially (year 7 and 9), and at year 
14 (18). 
Tumours reaching 20mm have a higher risk of becoming symptomatic, and this is often the 
critical point at which an intervention will be planned with the patient. 
Tumour size and grading 
First outlined in 1976, the Koos grading system(19) defines tumour extent, and has been 
used widely in the literature as a classification system over the past 4 decades.  
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Koos grading system: 
Grade 1 tumours are confined to the internal auditory canal. 
Grade 2 tumours extend into the CPA but doesn’t involve the brainstem.  
Grade 3 tumours encroach the brainstem. 
Grade 4 tumours have mass effect on the brainstem, may cause hydrocephalus and 
compress cranial nerves.  
A recent study published by Erickson et al has shown the Koos system to still be a valuable 
and reliable tool for characterizing ANs(20). Tumours may also be categorized by size into 
the following groups(6): 
Small:    1-10mm   
Medium:  11-20mm 
Moderately large: 21-30mm   
Large:   31-40mm 
Giant:   ≥ 41mm 
Presentation and symptoms 
Despite their non-malignant pathology, ANs can be associated with significant morbidity. 
Presenting symptoms are most commonly hearing loss, tinnitus and vertigo related to CN 
VIII involvement. Less frequently, compression of the trigeminal and/or facial nerve (CNs V 
and VII respectively) results in facial numbness, weakness or facial paralysis. Large and 
giant tumours may uncommonly lead to compression of the brainstem or cerebellum and in 
rare cases cause obstruction of the ventricular system resulting in hydrocephalus. 
Vestibulocochlear dysfunction (CN VIII): unilateral sensorineural hearing loss and tinnitus 
are the 2 commonest presenting symptoms in acoustic neuromas, present in up to 95% and 
63% of patients, respectively, (21). Unsteadiness is also frequent, seen in one study in 61% 
of patients at presentation, with true vertigo being less common. 
 Degree of hearing loss at audiogram is assessed using the Gardner-Robertson 
classification system(22). Pure tone audiogram and speech discrimination are scored as 
follows, and hearing classified from I-5: 
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Gardner-Robertson Classification Speech 
discrimination 
Pure tone 
audiogram 
Class 1 (good) 70-100% <30dB 
Class 2 (serviceable) 50-69% 31-50dB 
Class 3 (non-serviceable) 5-49% 51-90dB 
Class 4 (poor) 1-4% >91dB 
Class 5 (none) 0% none 
 
Classes I and 2 are considered serviceable hearing, and classes 3-5 non-serviceable. 
The facial and trigeminal nerves (CN VII and CN V respectively) closely follow the course of 
CNVIII through the base of skull and patients may present with neuropathies of these cranial 
nerves. 
Facial nerve dysfunction (CN VII): compression of the facial nerve by ANs (seen in 6% of 
patients (21)) may cause varying degrees of facial weakness, and uncommonly taste 
disturbance and xeropthalmia may be seen. Facial paresis is graded using the House-
Brackmann scoring system I-VI(23) 
Grade I Normal 
Grade II Mild dysfunction (slight weakness, normal symmetry at rest) 
Grade III Moderate dysfunction (obvious but not disfiguring weakness with synkinesis, 
normal symmetry at rest) Complete eye closure with maximal effort, good 
forehead movement 
Grade IV Moderately severe dysfunction (obvious and disfiguring asymmetry, 
significant synkinesis) Incomplete eye closure, moderate forehead movement 
Grade V Severe dysfunction (barely perceptible movement) 
Grade VI Total paralysis 
Trigeminal nerve impairment (CN V): occurs in 9% of AN patients(21), and presents as facial 
numbness, facial pain or trigeminal neuralgia along any or all the branches of CNV 
(ophthalmic, maxillary or mandibular branches) 
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Other neurological symptoms including ataxia, dizziness, headaches, vomiting may also be 
presenting symptoms in cases of large tumours having a pressure effect on the brainstem or 
cerebellum, or due to hydrocephalus. 
Radiological diagnosis 
Unilateral sensorineural hearing loss is the usual presenting complaint prompting patients to 
seek medical attention. CT scans were initially used as the diagnostic modality until the mid 
1980’s when MRI became commercially available. The addition of gadolinium (Gd) to MRI 
further improved imaging, and this is now the standard of care. Typically, ANs enhance with 
Gd contrast on MRI and CT, and are noted to expand the IAC on bony windows on CT. 
Up to 12% of ANs are discovered incidentally (24), and these asymptomatic and minimally 
symptomatic ANs pose a therapeutic dilemma, due to their variable natural history(4, 12, 17, 
25). Many lesions remain stable over long periods of time displaying slow growth of 1 to 
2mm/year. However, others grow more rapidly, enlarging upward of 2-4mm annually while 
still others may show growth and then spontaneous regression (4, 17).  
Evolution of treatment  
ANs may be treated with several modalities: historically this was surgery (26). More recently 
treatment options are “wait and scan”, microsurgery and stereotactic radiosurgery/ 
radiotherapy has been added to the armamentarium(2).  
Patients with cystic tumours and NF2 require special mention. Radiotherapy is not 
recommended for cystic lesions, as this modality may induce rapid enlargement, causing 
significant morbidity and may be life threatening (17). In NF2, as patients frequently have 
bilateral ANs and are at risk of other central nervous system tumours, management should 
be individualized (27). Hearing preservation is of the utmost importance.  
Observation 
A “wait and scan” approach is controversial, but is an acceptable option where tumours are 
indolent on serial imaging and patients are not experiencing unacceptable symptoms (2, 6, 
17). This is also a valid option in elderly patients who are not fit for surgery and in those who 
decline intervention. Hearing loss is, however, a risk in this strategy as it has been described 
in up to half of patients (28). In younger patients with small tumours and good hearing, the 
recommendation at the 7th International conference on acoustic neuromas is for early 
intervention (29).  
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Surgery 
Sub-total resection of an acoustic neuroma was first described by Balance in 1907(26). 
Tumours were usually large and symptomatic at presentation, with significant morbidity from 
both the tumour and its surgical resection. Mortality rates described were up to 84%(30) and 
cranial neuropathies were severe post-surgery. 
Microsurgery 
With the development of microsurgery, newer surgical techniques and increased expertise, 
outcomes have vastly improved over the past few decades. Mortality post-surgery is now 
very low, with rates of 0.2-1% reported (31-33). Approaches include retrosigmoid, to 
preserve serviceable hearing; translabyrinthine for the removal of large lesions and where 
hearing has already been lost, and via the middle cranial fossa in lesions of <1.5cm. 
Subtotal resection is intentionally done in some cases with a view to hearing or facial nerve 
preservation, but complete resection is usually feasible. Where resection is incomplete, 
recurrence can occur in up to 15%(34). Surgical debulking in large tumours for symptom 
relief is followed by SRS to ensure LC rates are improved. 
Other commonly reported significant surgery-associated morbidity is trigeminal nerve fallout, 
facial nerve damage and less commonly CSF leaks, infections and vascular complications. 
Intraoperative monitoring of cranial nerves improves facial nerve and vestibulocochlear 
nerve damage.  
Stereotactic radiosurgery and radiotherapy 
Stereotactic radiosurgery (SRS) using cobalt sources was first introduced in the 1950s 
(Leksell Gamma Knife), with a fixed head frame for immobilisation. Doses of a single 16Gy 
fraction were initially delivered, but significant rates of facial paralysis and numbness were 
seen (27). Subsequent dose reduction to 13Gy (to the marginal dose) has resulted in 
improved CN toxicities and similar tumour control rates to the higher dose(35). Patients can 
be treated as outpatients, and there is no post-operative recovery period required compared 
with surgery. 
Subsequently, linear accelerators (LINACS) have been adapted to enable delivery of SRS 
without head frames. Online image guidance facilitates accurate positioning of patients and 
allows a high dose to be delivered to the tumour volume with submillimeter accuracy (36, 
37). Conventional fully fractionated RT (FSRT), hypofractionated stereotactic radiotherapy 
(SRT) and single fraction stereotactic radiosurgery (SRS) have all been used with excellent 
outcomes(35, 37, 38).  
  
	 19	
Current treatment guidelines 
Reports have shown lower morbidity and no mortality with radiotherapy compared to surgical 
treatment of ANs(39, 40). In 2013 Wolbers et al published a review of 6 controlled studies 
comparing microsurgical and radiosurgical outcomes for the treatment of small and medium 
ANs (<30mm). All showed better outcomes in those patients treated with radiosurgery(33). 
Persistent sensori-neural hearing loss is common, regardless of the treatment modality 
used, and rarely improves post-microsurgery or post-SRS. Rates of functional hearing 
preservation quoted in the literature are variable, with 2 recent reviews describing 
microsurgical preserved hearing rates of 0-40%(33) versus 25-75 % for SRS (33, 41). 
Fractionation of radiotherapy exploits the radiobiological repair of normal tissues, and may 
improve hearing preservation (42). 
SRS has become the gold standard for managing small and medium sized AN tumours. In 
addition to short treatment time, SRS has the benefit of outpatient treatment, no post-
operative recovery period and no surgical morbidity. Recent literature reviews describe 
various fractionation regimens, some comparing tumour control with SRS versus SRT (33, 
36). Hearing preservation rates for SRS historically were 51% (43, 44) but with dose de-
escalation and current marginal doses of 12-14Gy, large series report hearing preservation 
rates of between 41-79%  for Gamma knife (2). Multiple studies such as Meijer et al and 
Collen et al have directly compared single fraction SRS with SRT and found no significant 
benefit for hearing preservation using fractionated RT(45). 
In terms of other cranial nerve function, high rates of preservation of facial nerve (95-100%) 
(2)and trigeminal nerve (99-100%)(42, 46) function is reported for SRS and SRT. No 
significant differences have been described in studies comparing hypofractionated regimens 
with SRS (2, 47).However, there is a still a paucity of data describing hypofractionated 
methods, and to the author’s knowledge, none using photons have been published in South 
Africa. 
 
Radiological tumour measurement and definition of tumour control 
ANs are asymmetrical “ice-cream cone” shaped tumours with different growth patterns 
depending on whether they are purely intra-canalicular or involve the CPA. This makes 
accurate measurement challenging. Both the method of measurement of ANs and the 
definition of tumour control post treatment are poorly defined in the literature (12, 48). The 
American Academy of Otolaryngology –Head and Neck Surgery defines a method 
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measuring the square of the mediolateral x anteroposterior dimension of the tumour(49). 
This method is however not utilized in the literature or in practice.  
Traditionally, radiological evaluation of tumour growth has been according to the RECIST 
criteria using change of maximal linear diameter(MLD). This estimates 3D tumour volume, 
using 2D tumour diameter, and assumes symmetrical growth. Given the irregular 
dimensions of the ANs, MLD on MRI is less accurate than tumour volume, and can result in 
gross underestimation of tumour growth and regression rates (12). Using an equation cited 
by a Hong Kong group for tumour volume (50) 
V (volume) = k (constant) x D3 (maximal diameter)  
a 10mm lesion which shrinks by 30% will only show a 1mm reduction in diameter. 
 Stangerup et al, who have the largest prospective observational study in the natural history 
of ANs, defined growth for intracanalicular lesions as extension of the tumour to involve the 
extrameatal region. Extrameatal lesions’ growth was defined as >2mm growth in 
diameter(17).  
These various methods of measurement of tumour response post treatment make it difficult 
to compare outcomes. Also,  studies do not adequately define what is meant by tumour 
control, and where defined, there is variation as to the cutoff for growth (the literature quotes 
1-3mm change in MLD) (51). It has been previously shown that radiologists cannot 
accurately or reproducibly measure change in tumour size of less than 2mm(51). 
More recent studies (52, 53) have highlighted the inaccuracies of 2D measurement and 
validated volumetric measurements to assess tumour response to therapy; there is 
increasingly a trend in the literature to describe tumor control in terms of tumour volume, and 
has previously been defined as less than a 20% increase in tumor volume (TV), measured in 
cubic centimeters, after a minimum of 24 months of imaging(46, 50, 52, 53). 
At the 7th International Conference on Acoustic Neuromas, held in Shanghai in 2016, 
radiotherapy radiological outcomes were graded 1 to 3: grade 1 tumours were controlled, 
with diameter reduction of >2mm and >10% reduction in tumour volume; Grade 2 tumours 
were stable (tumour diameter reduction<2mm and volume<10%; grade 3 tumours exhibited 
growth(29). 
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In addition to the lack of consensus in the literature on the precise definition of AN growth 
after radiotherapy, it is also unclear which of these patients whose tumours enlarge indeed 
require additional intervention (microsurgery or repeat SRT). In his 2006 analysis of ANs that 
grew after SRS, Pollock quotes enlargement in as many as 14% of 208 patients treated with 
SRS between 1990 and 2001. Median tumour volume increase was 70%. He describes 3 
“types” of enlargement Type 1 tumours initially enlarge and then shrink back to a similar pre-
treatment size; type 2 tumours enlarge and remain larger than their original volume, but do 
not progress and type 3 tumours are characterised by progressive growth on serial 
imaging(54). He postulates that it is only type 3 tumours who may benefit from further 
intervention. 
There is no definitive schedule for imaging. It is well documented that ANs show transient 
increase in size in the 9- 18 months’ post SRS and SRT(2, 29, 50), before stabilizing or 
decreasing in size. Post RT imaging schedules should account for transient oedema by 
delaying initial post-RT MRI to prevent unnecessary early intervention (2). However, the 
International Stereotactic Radiosurgery Society (ISRS) guidelines do not prescribe follow-up 
imaging intervals(2). 
One institution in the Netherlands suggests initial follow-up MRI after 2 years, and the next 
at 5years (45) At our institution we scan annually for 5 years, and biennially thereafter. 
 
Our setting 
Where SRS is the gold standard globally in the treatment of small to medium sized ANs, in 
the low and middle income country (LMIC) setting such as ours, resource constraints mean 
that expertise and equipment dictate management of AN patients.  
This GSH technique was recently described and validated in a separate study (55) as a 
dosimetrically acceptable alternative to SRS.  As a follow-on study, planned to assess the 
radiological tumour control and clinical symptoms in this group of patients treated with the 
described regimen of hypofractionated SRT. Tumour control rates and pre-defined 
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symptoms, i.e. hearing preservation, facial nerve and trigeminal nerve dysfunction, and other 
neurological symptoms, will be described and compared with that described in the literature 
as being achievable by SRS(36). We also wish to assess how accurate radiologist reported 
2D MLD were after treatment as a measure of calculated tumour volumes. 
A simple abbreviated course of radiotherapy, which is safe and effective, has advantages for 
both patient and service provider in that the patient is spared a protracted course of 
treatment, and the radiotherapy resources are optimally utilized. It is hoped that this 
hypofractionated IGRT alternative technique will be able to be utilized by similar resource 
constrained settings.  
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Introduction 
Acoustic neuromas (AN) are common benign intracranial lesions arising from myelin 
producing Schwann cells of the vestibulocochlear nerve (Cranial Nerve VIII). They make up 
80-85% of cerebellopontine angle (CPA) tumours (1, 2). With improved access to MRI in the 
past decade, their apparent incidence has increased to 20 per million/year(3, 4) and median 
size has decreased (3). Most ANs arise sporadically and are unilateral, but they may be 
associated with neurofibromatosis type 2 (NF2), where they are frequently bilateral and may 
associated with other tumours. ANs have an intracanalicular (internal auditory canal) portion, 
limited in terms of expansion by bony anatomy, and may extend into the cerebello-pontine 
angle (CPA) giving them a classic “ice-cream cone” shape. 
Clinically ANs most commonly present initially with hearing loss, tinnitus and vertigo. Rarely, 
trigeminal and facial nerve involvement (cranial nerves V and VII respectively) leads to facial 
numbness, weakness or facial paralysis. Large CPA lesions may cause brainstem 
compression. They are grouped by size into small (1-10mm), medium (11-20mm) 
moderately large (21-30mm), large (31-40mm) and giant (>41mm)(5). Tumors are also 
classified by the Koos grading system, which describes the extent of the tumour by degree 
of extrameatal extension and brainstem compression: Grade I lesions are purely 
intracanalicular; grade II tumours extend into the CPA, not reaching the pons;  grade III 
tumours reach the pons and grade IV tumours deform the pons and shift the 4th ventricle (6) 
ANs display a variable natural history  (5, 7) and management options vary accordingly: - 
options include a “watch and scan” approach, surgery and radiotherapy.  
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Observation may be appropriate in small tumours exhibiting slow growth (1-2mm/year). 
Morbidity of treatment must be weighed against patients’ symptoms. 
However, when lesions are larger or growth is more rapid, microsurgery or stereotactic 
radiosurgery (SRS) becomes necessary to prevent compressive symptoms.  
Surgical outcomes have vastly improved over the past 2 decades with increased expertise 
and newer techniques. Mortality post-surgery is low, with rates of 0.2-1% reported(8-10). 
Standard approaches are retrosigmoid to preserve serviceable hearing, translabyrinthine 
(suggested for removal of large lesions and where hearing is lost(11) and the middle cranial 
fossa approach in <1.5cm lesions(12). Surgery should be done in high volume centres of 
excellence to reduce morbidity and mortality. Subtotal or gross total resection may be 
attempted for small or large lesions, with consideration given to tumour location and 
anticipated operative risks, as well as neurosurgical experience. 
Over the past 2 decades, since the advent of Gamma Knife surgery, SRS has become the 
gold standard in the treatment of AN’s <2cm because of improved functional outcomes when 
compared to surgery (13, 14). In addition to short treatment time, SRS has the benefit of 
outpatient treatment, no post-operative recovery period and no surgical morbidity.  
Recent literature reviews describe various fractionation regimens, some comparing tumour 
control with SRS versus SRT (4, 10) However, there is still a paucity of data describing 
hypofractionated SRT, and to the authors’ knowledge, none describing use of photons has 
been described in South Africa. 
In poorly resourced settings such as South Africa, access to highly skilled neurosurgeons, 
otorhinolaryngologists and sophisticated RT is limited, posing a problem for the 
management of these patients. Groote Schuur Hospital (GSH) treated 25 AN patients from 
2008 to 2012 with SRS, using a Radionics system. When this became defunct, SRS was no 
longer an option for state sector patients. A 6MV Varian Unique ™ was installed in 2013, 
with megavoltage image-guided radiotherapy (IGRT) software allowing for accurate 
repositioning of patients to within 1.5mm. Using the new Unique™, a modified 
hypofractionated dynamic conformal arc (DCA) technique was developed and implemented 
for treatment of small and medium sized ANs. Patients received 3 daily fractions of 6.4Gy 
per fraction, to a total dose 19.2Gy delivered within one week. This technique is described 
by Burger et al in a prior publication(15). 
There is no data describing outcomes of AN patients in South Africa treated with SRT using 
photons. We describe demographics and clinical and radiological outcomes of AN patients 
treated with a modified SRT technique at a single academic centre in Cape Town, South 
Africa. 
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Research methods  
Patients and symptoms 
Of fifteen AN patients who were retrospectively identified from the planning database as 
having received DCA SRT between February 2013 and January 2016, 13 were included in 
the study. Three patients did not have follow-up imaging after treatment, and are discussed 
separately. 
 One patient was excluded as radiologically he had a trigeminal nerve schwannoma. A 
second was excluded due to dose reduction and inadequate tumour coverage, to ensure the 
brainstem dose constraint was met. All patients were over 18 years old and were permitted 
to have had previous surgery to their tumours.  
Clinical information was extracted from radiotherapy folders at baseline and follow-up visits. 
Patients’ demographics (age, gender, ECOG performance status at baseline), tumour 
characteristics (previous surgery, Koos grade, size and laterality) symptoms including CN V, 
VII and VIII neuropathies, and length of follow-up were all recorded.  
Follow-up and imaging 
 Clinical follow-ups were planned for six weeks after RT, then 6 monthly for 1 year, annually 
until 4 years and biennially thereafter. MRIs were scheduled annually after completion of 
SRT for the first 4 years, and biennially thereafter. However, in practice, the frequency of 
clinical follow up and imaging varied. Three patients had no follow-up MRIs after treatment 
and mean duration of follow-up was 35,1months (range 0-50months). 
Tumour measurement and control 
For each MRI, maximal linear diameter (MLD) was recorded, as measured by the radiologist 
according to RECIST criteria for solid tumours. A 2mm change from the previous scan was 
deemed to be significant growth or shrinkage.  
The baseline MRI was fused to the planning CT and was used at time of radiotherapy 
planning to delineate the gross tumour volume (GTV). This volume was used for this study 
as the baseline tumour volume (BTV) per patient for the study. Follow up MRI images were 
imported into the Eclipse™ treatment planning system (TPS) and fused to the original 
planning CT. The tumour on serial scans was contoured by the author using the gadolinium 
enhanced T1W images, and TV calculated by the treatment planning system (TPS). 
Volumes were validated by a second investigator. 
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To account for transient tumour expansion, tumour control was defined using follow up MRI 
scans done at least 12 months from the time of treatment, unless an increase from BTV of 
≥20% was seen. Patients were censored at time of last MRI. 
Correlation of radiologist tumour measurements with calculated tumour 
volumes 
For this correlation, radiologist reported 2D measurements (maximum linear diameter, TV or 
AP in mm) and calculated tumour volume (TV) was depicted graphically for each MRI.  
To determine if the radiologist’s assessment of increase in tumour size at last follow-up scan 
(i.e. 2mm larger) can be confidently used to diagnose tumour growth, the sensitivity, 
specificity and accuracy were calculated: 
 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 = 𝑇𝑃/(𝑇𝑃 + 𝐹𝑁)	
	 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 = 𝑇𝑁/(𝑇𝑁 + 𝐹𝑃)	
	 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 = (𝑇𝑁 + 𝑇𝑃)/(𝑇𝑃 + 𝐹𝑃 + 𝐹𝑁 + 𝑇𝑁)	
Where:  
TP is true positive (i.e. radiologist reports growth where there IS increase in tumour 
volume) 
TN is true negative (where radiologist reports stable/smaller tumour where there IS 
NO increase in tumour volume) 
FP is false positive, and FN is false negative. 
Assessment of hearing and facial nerve dysfunction 
Hearing was graded using the Gardner-Robertson classification as serviceable (Grade I-II) 
or non-serviceable (Grade III-V), using available clinical and audiogram information. Facial 
nerve dysfunction was scored using the House-Brackmann system (Grade I being normal, 
grade II is mild dysfunction, grades III and IV are moderate and moderately severe 
dysfunction, grade V is severe dysfunction and grade VI is total paralysis). 
Tumour size classification 
The Koos classification was used to categorize tumours using available radiological 
information.  
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Radiotherapy treatment planning  
For radiotherapy planning, all patients had a localisation Gd-contrasted MRI. Images were 
imported and fused with the contrasted planning CT on the Varian Eclipse™ treatment 
planning system. The GTV was drawn using the enhancing tumour on the MRI, and a 2mm 
margin expanded to the PTV to account for setup error as stereotactic equipment was not 
available. For this study, the GTV was used as the initial tumour volume, with no margin. 
The dose was prescribed to the 80% isodose line, and renormalized to 100%, as per RTOG 
quality assurance guidelines for radiosurgery(16).  
Treatment and quality assurance 
For scanning and treatment, patients were immobilised using a 5-point head and shoulder 
thermoplastic mask, fitted to a carbon-fibre S-frame. Daily online orthogonal 2D-2D MV 
advanced image matching was performed, with automatic repositioning of patients in the 
longitudinal, lateral and vertical directions to ensure geometric accuracy of treatment 
delivery.  
Data analysis and statistical considerations 
Demographics, clinical information and tumour characteristics were descriptive, and the 
analysis of data displayed using tables and charts expressed as means and percentages.  
Hearing was scored by Gardner-Robertson classification, using available clinical and 
audiogram information. Facial nerve dysfunction was scored using the House-Brackman 
grading. Frequency of clinical symptoms pre- and post treatment was expressed as 
percentages and analysis was descriptive. 
Tumour progression was defined as ≥20% increase from baseline GTV, and tumour control 
was depicted on a Kaplan-Meier curve. Events were determined from time of time of 
treatment to confirmed tumour growth as seen on MRI. Patients were censored at time of 
their last MRI. 
The Spearman correlation was used to correlate radiologist MLD and calculated TV. 
For statistical tests performed, a p-value of <0.05 was considered significant. Graph Pad 
Prism version 7.0 was used for data evaluation. 
Ethical consideration 
Approval for the study was obtained from the University of Cape Town’s Faculty of Health 
Sciences Human Research Ethics Committee (HREC REF: 385/2018) 
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Results 
Patient and tumour characteristics 
The mean age of the 13 patients included was 60.4years (range 45-79 years), with 4 
(30.8%) being female. Demographics and tumour characteristics are shown in table 1. Most 
patients were considered to be well at their initial visit, having an ECOG performance status 
of 1(92.3%) or 2 (7.7%). Seven patients (53.8%) had left sided tumours and median tumour 
size was 1.15cm3 (mean 1.59 cm3 and range 0.62-3.35 cm3). Nine patients (69.2%) had 
Koos stage 2 ANs, 3 (23.1%) had stage 3 tumours and 1 (7.7%) had a stage I tumour. 
Two patients had NF2, one of whom (patient 1)  had surgical debulking of her tumour 11 
months prior to her SRT. She was also found to have a contralateral AN which is being 
managed with observation. 
The median follow-up time was 29 months (range 0-50 months). Five deaths occurred 
during follow-up; 3 died of other illnesses, 1 folder (patient 12) was lost and her cause of 
death is unknown and one patient likely demised of advanced age. These are discussed 
below.  
The median BTV, as calculated by the treatment planning system (TPS), was 1.15 cm3 
(mean 1.59 cm3 with range 0.62-3.35 cm3).  
 
Table 1.Patient and tumour characteristics 
 
 N (%) 
Gender  
             Female 
             Male 
 
4 (30.8%) 
9 (69.2%) 
Age (y) at initial visit 
             Mean 
 
 
60.4y 
Range 45-79y 
Tumour location 
             Left 
             Right 
 
7 (53.8%) 
6 (46.2%) 
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Koos classification 
Stage I (intracanalicular) 
Stage II (CPA) 
Stage III (CPA reaching pons) 
Stage IV (deforming pons shifting 4th ventricle)  
 
1   (7.7%) 
9   (69.2%) 
3   (23.1%) 
0 
Alive 
          Yes 
          No 
           
 
8 (61.5%) 
5 (38.5%) 
 
Previous surgery 
          Yes 
           No 
 
2 (15.4%) 
11 (84.6%) 
Tumour size (MLD) 
        <10mm 
        11-20mm 
        21-30mm 
        31-40mm 
        >41mm 
 
 
0 
12 (92.3%) 
1 (7.7%) 
0 
0 
ECOG  
            0 
            1 
            2 
            3/4 
           
 
0 
12 (92.3%) 
1 (7.7%) 
0 
 
Neurofibromatosis type II 2 (15.4%) 
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Figure 1.Individual tumour response trend after SRT  
 
Figure 1 graphically shows individual tumour control after SRT over time. Transient tumour 
growth is noted in patients 1, 6 and 10 in their early scans (months 12, 11 and 12 
respectively). Growth is also noted in early scans for patient 11  (month 18), but in the 
absence of surveillance imaging it’s not clear if this is transient or true growth. Sustained 
growth is seen in patients 4 and 5. 
 
0 12 24 36 48 60
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
Months since RT
Tu
m
ou
r v
ol
um
e 
in
 c
m
3
Tumour response curve
1
2
3
4
5
6
7
8
9
10
11
12
13
	 36	
Tumour control 
Three patients did not have follow-up imaging. The mean MRI follow-up time for the 
remaining 10 patients was 35.1 months (range 18-50 months).  
Three patients had radiological progression (≥20% increase) in TV post RT: one (patient 11) 
exhibited growth of 34.4% at his 18month MRI. He is due for a subsequent scan and retains 
useful hearing. 
The other 2 patients who progressed (patients 4 and 5) had increases in their calculated TV 
of 23.5% at 38 months  and 60.16% at 36 months respectively. Their last MRIs showed 
ongoing growth of 35.04% and 79.67% at  50 and 43 months respectively.   
Multidisciplinary discussion regarding further intervention for both patients is ongoing 
(discussed below). None of these 3 patients who progressed had NF2. 
The remaining 7 patients had stable lesions, with 4 exhibiting ≥20% tumour regression. 
 
 
 
Figure 2. Changes in tumour volume from Baseline  
C. Wilcoxon plot depicting pre- and post-RT volumes for 10 patients , at time of 
last imaging (range 18- 50 months) . Maximum, minumum and median TV are 
depicted by the superior, inferior and middle lines. 
D. Waterfall plot showing post treatment volumes.  Stable disease is between 
the dashed lines ( -20% and +20% change in tumour volume).Tumour 
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progression can be seen in 3 patients, stable disease in 3 patients, and 
regression in 4 patients.  
Tumour control was depicted on a Kaplan Meier curve (fig 2). Tumour control at 36 months 
was 74%. Three patients had progression, showing an increase of TV of 34.4%, 60.16% and 
23.5% at 18, 36 and 38 months respectively. 
 
 
 
Figure 3. Kaplan-Meier curve showing radiological tumour control after hypofractionated 
SRT 
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Symptom outcomes 
Baseline symptoms 
Symptoms at baseline included vestibular-cochlear (VIII) related symptoms, namely tinnitus 
in 8 (61.5%), non-serviceable hearing (Gardner Robertson grade III-V) in 10  (76.9%) and 
ataxia in 7 of 13 patients (53.8%). Facial nerve (CN VII) dysfunction (House-Brackman 
grade II) was noted in one patient (7.7%) and trigeminal neuralgia (CN V)  in 2 patients 
(15.4%). One patient (patient 12) had a facial nerve palsy (House-Brackmann grade VI) prior 
to her initial visit and SRT. This resolved after attempted biopsy and debulking of the lesion, 
which was found to be attached to the facial nerve (see discussion). 
 
CN VIII  outcomes 
Non-hearing symptoms 
Of the 8 patients experiencing tinnitus prior to RT, one case resolved after RT, 3 had 
persistent symptoms and 4 patients had no documentation of the presence or absence of 
tinnitus.  There was one new case of tinnitus patient 1 with NF2 in the contralateral ear in 
which a new AN was seen on follow-up imaging.  
Ataxia was present at baseline in 7 patients: 4 patients’ symptoms resolved, 3 persisted. 
One patient had new onset imbalance post RT.  
Hearing symptoms  
Of the 3 patients with serviceable hearing pre RT, one became non-serviceable after 
treatment while the remaining 2(67%) continued to have serviceable hearing (Gardner 
Robertson grade II). Of the other 10 patients, 1 died (patient 20) and 9 did not recover 
serviceable hearing after treatment. 
 
CN V and VII outcomes 
The 2 patients (15.4%) with pre-treatment trigeminal neuralgia experienced persistent 
symptoms post treatment, and there were no apparent new RT-induced CN V symptoms.  
Mild CN VII dysfunction (House-Brackmann grade II) present in one of 13 patients (7.7%) 
resolved to normal function post therapy. Patient 11, who lives out of town and whose 
tumour had shown growth at his 18 month MRI, telephonically reported facial paralysis post 
RT. His GP reported it as a Bell’s palsy which resolved over some months. He has not seen 
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in our clinic after his treatment due to financial constraints, and sends his imaging for review 
by mail. 
Other symptoms 
Headaches that were reported by 2 patients(15.4%) prior to treatment resolved in both 
cases. 
No-one experienced nausea  or vomiting prior to or after radiotherapy. Dizziness was seen 
in 2 (15.4%) patients before treatment and this has persisted. New onset dizziness was also 
reported in a further 2 patients post-RT. 
 
Correlation of radiologist reported 2D TV versus calculated TV  
Radiologist reported axial measurements were plotted against calculated TV for MRIs (fig 4). 
 
Figure 4. Radiology correlation 
 
Spearman’s rank test showed good correlation between MLD and calculated TV 
(Spearman’s r=0.7394 p=<0.0001 (CI 0.5317 to 0.8632).  
 
When comparing radiologist reported increase in MLD (i.e. ≥2mm from baseline MRI) with 
calculated TV (i.e. change ≥20% from baseline volume), we looked at a total at 23 follow-up 
MRIs in ten patients. There was concordance between 18 of the 23 scans. Of the 5 scans 
where there was discordance between radiologist reported change and change in calculated 
TV (i.e. false positives), there was no instance where the radiologist underreported growth 
(i.e. no false negatives). In fact, in all 5 cases, MLD was reported as increased while 
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calculated TV was unchanged or decreased; in 2 cases, stable disease was reported where 
calculated TV showed decrease in TV and one case where MLD was smaller and calculated 
TV was stable. 
 
The sensitivity (positive predictive value) of the radiologist correctly identifying growth in 
tumour volume after treatment was 100% and specificity (negative predictive value) was 
77.3%. The accuracy of the radiologists’ assessment of whether there was a change in 
tumour volume was 82.1%. 
Discussion 
Since the advent of the Gamma Knife, SRS has become the gold standard for management 
of symptomatic small and medium sized ANs(2, 4, 10, 17, 18). Dose de-escalation over time 
has seen the reduction of marginal dose from 10-22.5 Gy to 12-14 Gy(19-21) with excellent 
local control of 89-99%(2), varying degrees of preservation of auditory nerve function and 
less morbidity of facial and trigeminal cranial nerves.  
With no access to SRS in our resource constrained setting, we piloted a hypofractionated 
IGRT DCA regimen for treatment of ANs using 6.4Gy/fraction to a total dose of 19.2Gy. 
Recent publication on this data has shown this method to be dosimetrically acceptable (15), 
and we retrospectively describe radiological tumour control and symptom outcomes for this 
cohort. 
Three patients in the initial cohort had only baseline imaging, and were thus excluded from 
the imaging follow up analysis for tumour volume. Of these 3, one patient is well and 
declines follow up. The other 2 demised- one patient (patient 13) died 13 months post 
treatment at 80 years after an emergency cardiac bypass. The second patient (Patient 12) 
demised 6 months post RT; her hospital folder was not found and it is unclear how she 
ultimately demised. At time of surgery, prior to her radiotherapy, she had a facial nerve palsy 
(House-Brackmann grade II/III) which resolved completely post debulking and biopsy. 
Biopsies of her small intracanalicular tumour prior to RT, showed only chronic inflammation. 
Intra-operatively the lesion was thought morphologically to be a schwannoma and was 
adherent to the facial nerve with extensive destruction of the cochlea and surrounding 
sphenoid bone. It is thus possible that she had a facial nerve or a cochlear schwannoma. 
Three further patients demised during their follow-up of causes unrelated to their tumour or 
treatment: Patient 6 was 77, and likely died of age related illness 2y and 6months after RT. 
Patient 7 died after a cardiac arrest and patient 10 demised from renal failure secondary to 
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sepsis, 3years and 2.5 years post RT respectively. The high number of deaths, proportional 
to the low numbers in our cohort contribute to the poor outcomes reported.  
ANs are asymmetrical “ice-cream cone” shaped tumours with different growth patterns 
depending on whether they are purely intra-canalicular or involve the CPA. This makes 
accurate measurement challenging, especially considering that tumour growth typically is 
estimated based on MLD on MRI. A small increase would be associated with a far greater 
volumetric expansion. Recent studies have highlighted the inaccuracies of 2D measurement, 
and proposed actual delineation of tumour volume as the preferred method(19, 22). In 
addition, tumour measurement is also variable across studies: some use MLD to assess 
growth (2mm being widely accepted), while more recent series use volumetric 
measurements. There is also much inter- and intra-radiologist variation in 2D tumour 
measurement, and it has been reported that variations of <2mm cannot be accurately 
measured (23). In our unit, most AN MRIs are reported on by experienced neuro-radiologists 
who see relatively high numbers of these tumours. However, some imaging is done 
elsewhere with non-standardised protocols and results may vary. For this reason, we wished 
to correlate radiologist 2D measurements and tumour volumetric expansion. Contrary to the 
literature, in our small study we found radiologist interpretation of change in tumour size was 
an accurate (82.1%) surrogate for the more accurate volumetric measure, with sensitivity of 
100% and specificity of 77.3%. However, our numbers are small and results may therefore 
be skewed.  
Tumour control for ANs after RT is not well defined on review of the literature, with some 
authors defining the endpoint for LC as being the lack of need for further intervention and 
others using radiological non-progression (19, 24, 25). Patel et al describes radiological 
response in their cohort, but ultimately defines LC as the “lack of need for surgical 
intervention”(24). Flickinger et al also reported LC as resection-free survival (97.1%) as well 
as neuroimaging control (91.0%). 
Various authors have compared 2D and volumetric modalities, and propose a change in TV 
of 19.7-20% as being significant for growth (26, 27).  Similar to small series reported by 
Vivas et al and Okunaga (27, 28) we defined radiological progression as >20% growth in TV 
from baseline. A recent literature review by Apicella et al quoted local control rates of >92% 
in series’ of patients with small ANs treated with radiotherapy (4). In this series there were 3 
studies using hypofractionated regimens similar to ours: 3 of 4 used 18Gy/3 fractions using 
photons while Vernimmen et al described their outcomes using protons (26CGyE/3 
fractions). All but one reported local control rates of >97%: in his cohort, Vivas et al describe 
reported LC rate of 83%, but specifies this is for radiological control; when reporting LC as 
the lack of need for further intervention in this group, this translates to 95%(28). Our small 
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series showed LC of 72% at 36 months which is significantly lower than that quoted in the 
literature with SRS and SRT.  We postulate this may be partly attributable to very small 
patient numbers, several unrelated deaths and short follow up time in this study, as well as 
our definition of LC as radiological non-progression while some other studies quote LC as 
lack of intervention.  
In addition to the lack of consensus in the literature on the precise definition of AN growth 
after radiotherapy, it is also unclear which of these patients whose tumours enlarge indeed 
require additional intervention (microsurgery or repeat SRT). In his 2006 analysis of ANs that 
grew after SRS, Pollock quotes enlargement in as many as 14% of 208 patients treated with 
SRS between 1990 and 2001. Median tumour volume increase was 70%. He describes 3 
“types” of enlargement Type 1 tumours initially enlarge and then shrink back to a similar pre-
treatment size; type 2 tumours enlarge and remain larger than their original volume, but do 
not progress and type 3 tumours are characterised by progressive growth on serial 
imaging(22). He postulates that it is only type 3 tumours who may benefit from further 
intervention. In our cohort, we saw growth in 3 of 10 patients  (30%) , which is double that 
seen in Pollock’s cohort and other studies (2, 29). At least 2 of these appear  to fall into Type 
3 of Pollock’s classification (patients 4 and 5) and they have been discussed in the 
multidisciplinary meeting whether surgery should be planned.  Neither patient was known to 
have NF2. This decision is complicated, and must consider change in imaging 
characteristics (e.g. increasing enhancement to suggest growth), patients choice and risk-
benefit ratio of further treatment. Patients 4’s calculated TV has increase by 35.04% at 50 
months; however his tumour showed less enhancement and more necrosis at his last 2 
MRIs compared with baseline. He is also not amenable to surgery, and so is being followed 
with serial MRIs. 
 Patient 5, although exhibiting significant tumour growth post SRT (79.67% at 43months post 
SRT) remains otherwise stable from her tumour symptoms. She is being managed with 
neuroleptics for trigeminal neuralgia that preceded her SRT, but  has multiple health issues 
that makes decisions for further intervention complex.   
Hearing loss was present in all of our patients, with only 3 having serviceable hearing 
(Gardner Robertson Grades1/2) at baseline. This may be a function of the delay in diagnosis 
from presentation to the patient’s primary health care facility, as well as resource constraints 
on our radiology services. Hearing preservation rates for SRS historically were 51% (17, 30) 
but with dose de-escalation and current marginal doses of 12-14Gy large series report 
hearing preservation rates of between 41-79%  for Gamma knife (2). Multiple studies such 
as Meijer et al and Collen et al have directly compared single fraction SRS with SRT and 
found no significant benefit for hearing preservation using fractionated RT. 
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In terms of other cranial nerve function, high rates of preservation of facial nerve (95-100%) 
(2)and trigeminal nerve (99-100%)(25, 31) function is reported for SRS and SRT. No 
significant differences have been described in studies comparing hypofractionated regimens 
with SRS (2, 32). Similarly, in our cohort, facial nerve preservation was 100% although, 
longer follow up is required to assess late toxicity. It is noted that older series using doses 
>13Gy for SRS had more cranial nerve toxicity and hearing preservation was not as high as 
in current series(33). Fully fractionated regimens of 5-6 weeks may theoretically further 
preserve remaining CN function by allowing repair of normal tissue, but has not translated to 
clinically significant differences in comparative studies (21, 32, 34, 35)However, lengthy 
treatment may not always be logistically desirable to patients, or possible in resource 
constrained settings with long waiting times. 
Our study has several limitations which may affect interpretation of results. This is a 
retrospective study, with a small cohort, and therefore may not reflect statistically significant 
differences in data. Some clinical and imaging data is missing, which may skew results and 
imaging was reported by various radiologists which may contribute to inter-reporter 
variability.  
Conclusion 
This is the first study looking at hypofractionated SRT in a local South African setting. While 
our cohort showed lower LC rates compared with similar published international 
hypofractionated cohorts, our numbers are small with relatively short follow up time and high 
attrition rates. No unexpected acute treatment toxicities were noted, but long term follow-up 
is needed to assess late RT effects. A prospective study in our centre using this method of 
treatment would better define LC. 
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